You are here: Industry Insights > Nabriva Therapeutics

News List

XENLETA Demonstrates High Efficacy in Community-Acquired Bacterial Pneumonia americanpharmaceuticalreview
October 16, 2020
Nabriva Therapeutics announced in a post-hoc analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 trials by age, XENLETA™ (lefamulin) demonstrated consistently high efficacy and similar safety and tolerability profiles across all ...
Nabriva Receives EC Approval for XENLETA for Community-Acquired Pneumonia americanpharmaceuticalreview
August 05, 2020
Nabriva Therapeutics announced the European Commission (EC) has issued a legally binding decision for approval of the marketing authorization application for XENLETA™ (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults ...
US FDA declines approval again for Nabriva’s antibiotic for UTI expresspharma
June 22, 2020
The company said it plans to request a meeting with the FDA to discuss the next steps.
Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for Intravenous Contepo (fosfomycin) for injection drugs
May 08, 2019
Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections ...